Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay et al. • 2014 • Horm Cancer. 2014;5(2):72-89.
© 2024 Corcept Therapeutics, Incorporated
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor et al. • 2013 • Clin Cancer Res. 2013;19(22):6163-72.
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.
Nanda et al. • 2016 • Springerplus. 2016;5(1):947.
Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.
Baker et al. • 2015 • Cancer Manag Res. 2015;7:361-8.
A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer
Nanda et al. • 2013 • Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-21.
Mifepristone inhibits GRβ coupled prostate cancer cell proliferation.
Ligr et al. • 2012 • J Urol. 2012;188(3):981-8.
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
Tieszen et al. • 2011 • BMC Cancer. 2011;11:207.
Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer.
Yan et al. • 2008 • Urol Int. 2008;81(2):228-33.
Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro.
Zhang et al. • 2008 • Zhonghua Wai Ke Za Zhi. 2006;44(6):382-5.
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer
Veneris et al • 2017 • Gynecol Oncol.